IL161291A0 - Human 3 relaxin - Google Patents

Human 3 relaxin

Info

Publication number
IL161291A0
IL161291A0 IL16129102A IL16129102A IL161291A0 IL 161291 A0 IL161291 A0 IL 161291A0 IL 16129102 A IL16129102 A IL 16129102A IL 16129102 A IL16129102 A IL 16129102A IL 161291 A0 IL161291 A0 IL 161291A0
Authority
IL
Israel
Prior art keywords
relaxin
human
Prior art date
Application number
IL16129102A
Other languages
English (en)
Original Assignee
Florey Howard Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florey Howard Inst filed Critical Florey Howard Inst
Publication of IL161291A0 publication Critical patent/IL161291A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
IL16129102A 2001-10-08 2002-10-02 Human 3 relaxin IL161291A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR8144A AUPR814401A0 (en) 2001-10-08 2001-10-08 Human 3 relaxin
PCT/AU2002/001338 WO2003030930A1 (en) 2001-10-08 2002-10-02 Human 3 relaxin

Publications (1)

Publication Number Publication Date
IL161291A0 true IL161291A0 (en) 2004-09-27

Family

ID=3831972

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16129102A IL161291A0 (en) 2001-10-08 2002-10-02 Human 3 relaxin
IL161291A IL161291A (en) 2001-10-08 2004-04-04 Use of h3 relaxin in the manufacture of medicaments for the treatment of various disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161291A IL161291A (en) 2001-10-08 2004-04-04 Use of h3 relaxin in the manufacture of medicaments for the treatment of various disorders

Country Status (9)

Country Link
US (4) US20050026822A1 (enExample)
EP (1) EP1434599A4 (enExample)
JP (1) JP2005508944A (enExample)
KR (1) KR20040063906A (enExample)
AU (4) AUPR814401A0 (enExample)
CA (1) CA2462892A1 (enExample)
IL (2) IL161291A0 (enExample)
NZ (1) NZ532216A (enExample)
WO (1) WO2003030930A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636384A4 (en) * 2003-06-20 2007-03-07 Amgen Inc GENEAVIFICATION AND OVEREXPRESSION IN CANCER
AU2003903124A0 (en) * 2003-06-20 2003-07-10 Mark Del Borgo Analogues of heteromeric proteins
JP4468304B2 (ja) 2004-02-09 2010-05-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スクリーニング方法
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
AU2005223694B2 (en) * 2004-03-19 2011-04-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
AU2011204972B2 (en) * 2004-04-30 2012-05-10 Corthera, Inc. Methods and Compositions for Control of Fetal Growth via Modulation of Relaxin
EP1753449A4 (en) * 2004-04-30 2009-09-23 Corthera Inc METHOD AND COMPOSITIONS FOR CONTROLLING FEDERAL GROWTH BY RELAXIN MODULATION
EP1846443A4 (en) * 2005-01-07 2008-07-23 Glaxo Group Ltd NEW USE
US20090311185A1 (en) * 2005-04-26 2009-12-17 Takayuki Hida Peptide having antianxiety activity and screening method therefor
WO2007027168A1 (en) * 2005-08-29 2007-03-08 Carrier Corporation Compressor muffler
ATE549351T1 (de) * 2007-01-30 2012-03-15 Janssen Pharmaceutica Nv Chimärer peptidantagonist für gpcr135 oder gpcr142
EP2373685A1 (en) * 2008-12-03 2011-10-12 F. Hoffmann-La Roche AG Process for preparing therapeutic peptide
KR101963460B1 (ko) * 2010-08-17 2019-03-28 암브룩스, 인코포레이티드 변형된 릴랙신 폴리펩타이드 및 그것의 용도
WO2012031328A1 (en) * 2010-09-08 2012-03-15 Howard Florey Institute Of Experimental Physiology And Medicine Treatments for substance abuse and addiction
EP2614075B1 (en) * 2010-09-08 2016-10-26 Howard Florey Institute Of Experimental Physiology And Medicine Single chain relaxin polypeptides
GB201110833D0 (en) * 2011-06-24 2011-08-10 Bold Venture Llc Compositions
CN102286092B (zh) * 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
WO2013095649A1 (en) * 2011-12-23 2013-06-27 Intel Corporation Apparatus and system for generating a signal with phase angle configuration
CN104133819B (zh) * 2013-05-03 2019-03-01 腾讯科技（深圳）有限公司 信息检索方法及装置
WO2015124540A1 (en) * 2014-02-19 2015-08-27 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
GB201516068D0 (en) * 2015-09-10 2015-10-28 Biomed Ltd B V Novel therapy
EP3458034A4 (en) 2016-05-18 2020-01-01 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING RELAXIN
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
CN114686427B (zh) * 2022-05-23 2022-07-29 中国人民解放军总医院第一医学中心 一种脾脏调节型b淋巴细胞及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5911997A (en) 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
US5753623A (en) * 1995-06-07 1998-05-19 Connetics Corporation Method of treatment for depression
JP2001012310A (ja) 1999-06-30 2001-01-16 Takemitsu Kurachi 水蒸気爆発により出力を増す内燃機関
US20020012967A1 (en) * 2000-03-10 2002-01-31 Holloway James L. Insulin homolog polypeptide zins4
EP1294887A1 (en) * 2000-03-10 2003-03-26 ZymoGenetics, Inc. Insulin homolog polypeptide zins4
US7049403B2 (en) * 2000-04-21 2006-05-23 Takeda Pharmaceutical Company Limited Insulin/IGF/relaxin family polypeptides and DNAS thereof
US7409403B1 (en) * 2001-10-30 2008-08-05 Red Hat, Inc. Alert management data infrastructure and configuration generator
US9206927B2 (en) 2012-05-18 2015-12-08 Brian K. Carter Utility conduit supporting device, system, and method

Also Published As

Publication number Publication date
WO2003030930A1 (en) 2003-04-17
US20050026822A1 (en) 2005-02-03
KR20040063906A (ko) 2004-07-14
EP1434599A4 (en) 2006-09-20
US20090239805A1 (en) 2009-09-24
AU2002331460B2 (en) 2008-01-24
AU2008201803A1 (en) 2008-05-15
US8841254B2 (en) 2014-09-23
CA2462892A1 (en) 2003-04-17
NZ532216A (en) 2007-05-31
IL161291A (en) 2011-01-31
AU2008201803B2 (en) 2011-06-30
JP2005508944A (ja) 2005-04-07
EP1434599A1 (en) 2004-07-07
US20080176795A1 (en) 2008-07-24
AU2009208063A1 (en) 2009-08-27
US20110003750A1 (en) 2011-01-06
AUPR814401A0 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
IL161291A0 (en) Human 3 relaxin
TW595857U (en) 091219345
IL159890A0 (en) Dolastatin 10 derivatives
GB0218205D0 (en) Human ZZAP1 protein
EP1251863A4 (en) 22 SEPARATE HUMAN PROTEINS
EP1254242A4 (en) 17 HUMAN SECRETED PROTEINS
EP1368468A4 (en) 83 HUMAN SECRETED PROTEINS
GB0111314D0 (en) Dermatological formulations
EP1370651A4 (en) 70 HUMAN SECRETED PROTEINS
EP1194439A4 (en) EAG2 OF HUMAN ORIGIN
GB0120009D0 (en) Cause and effect diagnosis
EP1317471A4 (en) 21 HUMAN SECRETED PROTEINS
EP1322657A4 (en) HUMAN SECRETED PROTEINS 22
EP1317472A4 (en) 17 HUMAN SECRETED PROTEINS
GB0410147D0 (en) Human angiomotin-like protein 1
EP1404807A4 (en) 20 SEPARATE HUMAN PROTEINS
EP1322659A4 (en) 21 HUMANE SECRET PROTEINS
EP1317467A4 (en) 7 HUMAN SECRETED PROTEINS
GB0201819D0 (en) Human posh-like protein 1
GB0201681D0 (en) Human ralgds-like protein 3
GB0226332D0 (en) Skin preparation
AU2002348034A8 (en) 16 human secreted proteins
AU9481201A (en) Human nedd-1
EP1311669A4 (en) 11 HUMAN, ELIMINATED PROTEINS
EP1313761A4 (en) 18 HUMAN SECRETED PROTEINS

Legal Events

Date Code Title Description
FF Patent granted